BMS builds big in Texas; Regeneron backs would-be rival

BMS reveals plans for a new manufacturing hub in Houston, and Regeneron invests in startup developing a Dupixent competitor.

By PharmaVoice Staff • Aug. 14, 2026

Drugs that missed the mark in pharma’s last earnings round

Why treatments from Alnylam, Merck, AbbVie and Roche stumbled in the last quarter.

By Kelly Bilodeau • Aug. 11, 2026

Brand-name drug denials are surging, especially for weight-loss

Nearly one-third of prescriptions included in a new study were rejected the first time a patient attempted to fill them.

By Alexandra Pecci • July 28, 2026

Compounders maintain a firm grip on the GLP-1 market

Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.

By Kelly Bilodeau • July 17, 2026

AstraZeneca aims for a new blockbuster run in cardio disease

With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight management and beyond, according to a company exec.

By Alexandra Pecci • June 1, 2026

Who’s winning pharma’s innovation race? The rankings are out.

While Eli Lilly reigns supreme, Idea Pharma’s annual R&D ranking reveals which other large pharmas are on the rise — and which are stumbling.

By Meagan Parrish • May 22, 2026

Novo hikes guidance on Wegovy pill’s fast sales start

Sales and profit should shrink less than originally anticipated thanks to strong momentum for its new obesity pill, the drugmaker said in its most recent earnings report. 

By Kristin Jensen • May 7, 2026

Predictive analytics in pharma turns lab data into launch strategies

Explore how diagnostic insights become launch strategies with predictive analytics and real-world lab data.

April 13, 2026

The FDA’s shame game

The agency is becoming more open about its criticisms of pharma companies and leaders, raising new privacy concerns in the industry.

By Kelly Bilodeau • March 30, 2026

Can Ocugen succeed where other gene therapy makers have struggled?

The biotech aims to quickly bring three gene therapies to market, and overcome the development and commercialization challenges that have dogged the space.

By Meagan Parrish • March 27, 2026

Gilead could potentially end HIV. But will it be able to?

After launching a PrEP medication that was 100% effective in clinical trials, the company is facing a complex global rollout and leveraging its network of partners for help.

By Meagan Parrish • March 20, 2026

Novo regained weight loss footing in the pill arena — but Lilly is coming

Eli Lilly has run away with the GLP-1 market. But can Novo Nordisk maintain pole position in the oral space?

By Alivia Kaylor • March 13, 2026

Bayer sets the stage for a pharma comeback

The pharma giant’s drug sales haven’t wowed in recent years. But that could soon change.

By Meagan Parrish • Feb. 6, 2026

Why TrumpRx is stumbling before it gets off the ground

Concerns about potential kickbacks, costs and conflicts have triggered calls for oversight.

By Kelly Bilodeau • Feb. 4, 2026

Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs

The GLP-1 giants are the first to try out this new model, but more companies may follow. 

By Kelly Bilodeau • Jan. 14, 2026

Hemophilia gene therapies are struggling on the market, even as innovation soars

The business case for hemophilia gene therapy still isn’t adding up due to persistent market barriers.

By Kelly Bilodeau • Dec. 3, 2025

As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones

Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a highly targeted patient approach.

By Kelly Bilodeau • Nov. 19, 2025

Is that pharma influencer human or AI?

Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.

By Meagan Parrish • Nov. 14, 2025

Drugs are winning approval even when trials fail — but should they?

About 10% of FDA-approved drugs in recent years have won clearance despite a trial failure, raising safety and ethical concerns.

By Kelly Bilodeau • Nov. 12, 2025

After a lackluster first drug launch, a new CEO is finding Geron’s commercial footing

Harout Semerjian, whose pedigree includes launching the Novartis cancer blockbuster Gleevec, is aiming to boost awareness about Geron’s Rytelo to give it momentum.

By Alexandra Pecci • Nov. 12, 2025

Alzheimer’s drug uptake hits its stride after a sluggish start

Sales of Eli Lilly’s Kisunla, and Eisai and Biogen’s Leqembi are on the rise as doctors grow more confident and new dosing options ease treatment hurdles.

By Kelly Bilodeau • Nov. 10, 2025

Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?

This week’s launch of subcutaneously administered Keytruda Qlex gives Merck a safety net for the cancer drug’s daunting patent cliff.

By Michael Gibney • Oct. 2, 2025

Is pharma’s IRA pricing battle running out of steam?

Despite recent court losses, the legal tides could still turn in the industry’s favor.

By Meagan Parrish • Sept. 26, 2025

A brewing GLP-1 showdown, from Big Pharma pills to a biotech implant

Newcomers looking for a way into the obesity space are developing unique methods to snag market share.

By Amy Baxter • Aug. 27, 2025

The biggest Big Pharma losers in the first half of 2025

What goes up must come down — here are the major drugs falling the hardest at the top companies so far this year.

By Michael Gibney • Aug. 21, 2025